Preliminary reports are mostly encouraging, indicating a more favourable biodistribution (e.g. [68Ga]Ga-FAPI, SSTR-antagonists), accuracy in particular settings (e.g. Exendin superiority over SSTR-agonist in the setting of insulinoma; [18F]F-MFBG superiority over [123I]I-MIBG) or potential theranostic use (e.g. [68Ga]Ga-PSMA, [64Cu]Cu-SARTATE, [68Ga]Ga-CXCR4). Here, CXCR4 is linked to pancreatic insulinoma.